Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9622184 | 0.80 | MAPT (0.36) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL31475345 | 0.80 | MAPT (0.47) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL8566803 | 0.78 | ALOX15 (0.44) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL15616434 | 0.77 | MAPT (0.41) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL5582938 | 0.77 | MAPK1 (0.36) | MAPTLMNAKMT2AMEN1HPGD | |
| SCHEMBL7494690 | 0.77 | SMN1; SMN2 (0.42) | MAPTLMNAKMT2AMEN1HPGD | |
| SCHEMBL29857810 | 0.77 | MAPT (0.41) | MAPTGAALMNAKMT2AMEN1 | |
| SCHEMBL2340132 | 0.77 | KDM4E (0.38) | MAPTLMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12179353 | 0.77 | MAPT (0.34) | MAPTGAAKMT2AMEN1HPGD | |
| SCHEMBL28760235 | 0.77 | MAPT (0.41) | MAPTGAALMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038357-A1 | SYNTHESIS OF SUBSTITUTED TETRACYCLIC CARBOXYLIC ACIDS AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-22 | — | — | WO | claimed |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| CN-121949288-A | Kezotinib preparation method of nylon | 广州科锐特药业有限公司 | 2026-05-01 | — | — | CN | disclosed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119707930-A | Aromatic ring compound and its prepn and use | 甘李药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240300941-A1 | HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF | Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) | 2024-09-12 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-11999725-B2 | HPK1 inhibitors, preparation method and application thereof | Zhuhai Yufan Biotechnologies Co., Ltd. (CN) | 2024-06-04 | — | — | US | disclosed |
| EP-2566858-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | Pfizer Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116050-A2 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2011138751-A2 | HETEROCYCLIC DERIVATIVES AS ALK INHIBITORS | PFIZER INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7618959-B2 | Antibacterial agents | SMITHKLINEBEECHAM CORP (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | disclosed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999725-B2 | HPK1 inhibitors, preparation method and application thereof | PGK1, HK1, PDXK | MAPT 3518/4885GAA 1604/4885LMNA 1621/4885 |
| US-20120220551-A1 | PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | PPM1A, PPM1G, PPM1B | MAPT 883/4885GAA 1320/4885LMNA 2892/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | MAPT 1102/4885GAA 1250/4885LMNA 2193/4885 |
| US-20070004710-A1 | Antibacterial agents | NQO2, NRDC, IFNG | MAPT 4448/4885GAA 314/4885LMNA 2488/4885 |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | ERBB2, ERBB3, ARRB1 | MAPT 4548/4885GAA 3217/4885LMNA 2496/4885 |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | MAPT 3454/4885GAA 806/4885LMNA 2145/4885 |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | MAPT 3687/4885GAA 895/4885LMNA 2258/4885 |
| US-20240300941-A1 | HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF | HK1, PGK1, PDXK | MAPT 3808/4885GAA 1743/4885LMNA 2143/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | MAPT 1151/4885GAA 1190/4885LMNA 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.